Abstract

Objective: To compare outcomes of diabetic foot ulcers (DFUs) treated with clostridial collagenase ointment (CCO) or silver-containing products, both in combination with sharp debridement as needed.Approach: One hundred two subjects with qualifying DFUs were randomized to daily treatment with either CCO or a silver-containing product for 6 weeks followed by a 4 -week follow-up period. The primary outcome was the mean percent reduction in DFU area. A secondary outcome was the incidence of ulcer infections between groups.Results: At the end of treatment, the mean percent reduction in area from baseline of DFUs treated with CCO was 62% (p < 0.0001) and with silver was 40% (p < 0.0001). The difference between groups—22%—was not statistically significant (p = 0.071). Among ulcers closed by the end of treatment, the mean time to closure was 31.1 ± 9.0 days versus 37.1 ± 7.7 days, respectively (not statistically significant). There was a numerically greater incidence of target ulcer infections in the silver group (11, 21.6%) than in the CCO group (5, 9.8%; p = 0.208). No clinically relevant safety signals were identified in either group.Innovation: CCO treatment can progress a wound toward closure. Ulcer infection prophylaxis may not be sacrificed when treating DFU with CCO in lieu of silver-containing products.Conclusion: Both CCO and silver-containing products promote significant reduction in DFU area over 6 weeks of treatment with no clinically relevant safety concerns. Mean percent reduction in lesion area was numerically (22%) but not significantly greater with CCO compared to silver, as was time to ulcer closure, with an incidence of ulcer infection at least as low as for silver-containing products.

Highlights

  • There are more than 22 million people in the United States with diabetes mellitus,[1] of whom up to 25%are at risk for the development of diabetic foot ulcers (DFUs).[2]

  • Qualifying lesions were present on any part of the plantar surface of the neuropathic foot or hallux at least 5 cm from any other DFUs, measured 0.5–10 cm[2] inclusive, were of at least 6 weeks and no more than 52 weeks duration, manifested no clinical signs or symptoms of infection, and required debridement

  • Twenty subjects were discontinued from the study before completion for the following reasons: 13 for adverse event, 4 for protocol deviations, and 1 each for loss to follow-up, withdrawal of consent, and nonadherence with study treatment

Read more

Summary

Introduction

There are more than 22 million people in the United States with diabetes mellitus,[1] of whom up to 25%. Are at risk for the development of diabetic foot ulcers (DFUs).[2] In the a Travis A. ADVANCES IN WOUND CARE, VOLUME 7, NUMBER 10 Mary Ann Liebert, Inc

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call